---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-041144"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:20:12.651757+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Interpace exchanges all Series B Preferred for Series C Preferred; first step toward Nasdaq uplisting

## Summary
- All 47,000 Series B Preferred shares (28,000 Ampersand, 19,000 1315 Capital) exchanged for Series C at $1,000 stated value.
- Series C converts at $2.02/share (date closing price), no liquidation preference, no director designation rights, limited protective provisions.
- Series C automatically converts to common upon Nasdaq uplisting; company believes Series C qualifies as stockholders' equity under GAAP.
- Amended investor rights agreement provides registration rights; prior support agreement with 1315 Capital terminated.
- Exchange is first step toward Nasdaq uplisting; no cash received; additional listing requirements may need to be satisfied.

## SEC filing metadata
- accession: 0001493152-24-041144
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315224041144/0001493152-24-041144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315224041144/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-041144
- JSON: https://secwatch.observer/filing/0001493152-24-041144.json
- Plain text: https://secwatch.observer/filing/0001493152-24-041144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.